Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study

Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study

Abstract Introduction Patients (pts) implanted with an ICD for a primary prevention (PP) typically receive concomitant medications (meds) to treat LV dysfunction. However, It is not well established whether compliance with guideline-directed medical therapy (GDMT) has improved over time in this popu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2023-11, Vol.44 (Supplement_2)
Hauptverfasser: Mont, L, Daubert, J, Kutyifa, V, Zareba, W, Ando, K, Wold, N, Yong, P, Schuger, C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title European heart journal
container_volume 44
creator Mont, L
Daubert, J
Kutyifa, V
Zareba, W
Ando, K
Wold, N
Yong, P
Schuger, C
description Abstract Introduction Patients (pts) implanted with an ICD for a primary prevention (PP) typically receive concomitant medications (meds) to treat LV dysfunction. However, It is not well established whether compliance with guideline-directed medical therapy (GDMT) has improved over time in this population. Methods Data were drawn from the MADIT-RIT (2009-2012) and APPRAISE ATP (2016-present) studies. Both studies were global in scope and enrolled pts who were implanted with an ICD for PP indications. Meds prescribed at baseline were compared between the two studies. Meds of interest included: evidence-based beta blockers [(BB-EV) defined as carvedilol, metoprolol, and bisoprolol], ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists (MRA). SGLT2i were introduced into GDMT after the study APPRAISE ATP started and were not included. Meds were analyzed both individually and in combination as GDMT, defined as joint use of BB-EV, ACE/ARB/ARNI, and MRA. Differences were compared with a t-test for continuous variables, a Chi-square test for categorical data and a Cochran-Armitage trend test for ordinal categorical data. Results Demographics for the two studies were compared for pts who received ICDs in MADIT-RIT (n=742) and APPRAISE ATP (n=2627 enrolled with n=2596 randomized) and are shown in the table below. When compared to MADIT-RIT, APPRAISE ATP pts were significantly older with a greater prevalence of diabetes. Comparison of baseline meds are shown in both the table and in the figure. Although BB-EV and ACE/ARB use was slightly but significantly lower in APPRAISE ATP, these declines were offset by a significant increase in MRA use in APPRAISE ATP. A marked shift was seen over time with significant decline in use of ACE-I that was matched by a significant increase in use of ARBs, either alone or in combination with ARNIs. When considering meds used in combination for GDMT, pts in APPRAISE ATP were significantly more likely to meet GDMT recommendations than pts who were enrolled in MADIT-RIT (36.7% vs 27.2%, respectively, p
doi_str_mv 10.1093/eurheartj/ehad655.344
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehad655_344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehad655.344</oup_id><sourcerecordid>10.1093/eurheartj/ehad655.344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2044-121012e40f6cb2bfb82eb56c36632b3fb85af80c8c05be626acfdc1d08c0ae313</originalsourceid><addsrcrecordid>eNqNkNFKwzAUhoMoOKePIJwX6JakTeiupMzpCgOHTvCupGliM2xTkmywV_Cpzdzw2pvz8x_Of87hQ-ie4AnBs3Sqdq5VwoXtVLWi4YxN0iy7QCPCKE1mPGOXaITJjCWc5x_X6Mb7LcY454SP0PdSeAitgp1XYDVI20vbmSD6AFK4xggJnWqMFMHY3oPpBmf3qoFYHATTKTA9DM50wh2iqr3qj5NQzh9hiKFo_QOUvTefbfCgne1-7xXr9WtRvi2g2KzBh11zuEVXWnx5dXfWMXp_Wmzmy2T18lzOi1UiKc6yhFCCCVUZ1lzWtNZ1TlXNuEw5T2mdRs-EzrHMJWa14pQLqRtJGhwbQqUkHSN22iud9d4pXZ3frwiujkCrP6DVGWgVgcYcPuXsbvhn5AenVoC6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Mont, L ; Daubert, J ; Kutyifa, V ; Zareba, W ; Ando, K ; Wold, N ; Yong, P ; Schuger, C</creator><creatorcontrib>Mont, L ; Daubert, J ; Kutyifa, V ; Zareba, W ; Ando, K ; Wold, N ; Yong, P ; Schuger, C</creatorcontrib><description>Abstract Introduction Patients (pts) implanted with an ICD for a primary prevention (PP) typically receive concomitant medications (meds) to treat LV dysfunction. However, It is not well established whether compliance with guideline-directed medical therapy (GDMT) has improved over time in this population. Methods Data were drawn from the MADIT-RIT (2009-2012) and APPRAISE ATP (2016-present) studies. Both studies were global in scope and enrolled pts who were implanted with an ICD for PP indications. Meds prescribed at baseline were compared between the two studies. Meds of interest included: evidence-based beta blockers [(BB-EV) defined as carvedilol, metoprolol, and bisoprolol], ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists (MRA). SGLT2i were introduced into GDMT after the study APPRAISE ATP started and were not included. Meds were analyzed both individually and in combination as GDMT, defined as joint use of BB-EV, ACE/ARB/ARNI, and MRA. Differences were compared with a t-test for continuous variables, a Chi-square test for categorical data and a Cochran-Armitage trend test for ordinal categorical data. Results Demographics for the two studies were compared for pts who received ICDs in MADIT-RIT (n=742) and APPRAISE ATP (n=2627 enrolled with n=2596 randomized) and are shown in the table below. When compared to MADIT-RIT, APPRAISE ATP pts were significantly older with a greater prevalence of diabetes. Comparison of baseline meds are shown in both the table and in the figure. Although BB-EV and ACE/ARB use was slightly but significantly lower in APPRAISE ATP, these declines were offset by a significant increase in MRA use in APPRAISE ATP. A marked shift was seen over time with significant decline in use of ACE-I that was matched by a significant increase in use of ARBs, either alone or in combination with ARNIs. When considering meds used in combination for GDMT, pts in APPRAISE ATP were significantly more likely to meet GDMT recommendations than pts who were enrolled in MADIT-RIT (36.7% vs 27.2%, respectively, p&lt;0.001). Conclusions In the APPRAISE ATP study, compliance with GDMT in PP ICD pts has significantly improved when compared to the MADIT-RIT study conducted 10 years previously. These changes have been characterized by greater use of MRAs as well as a shift away from ACE inhibitors towards use of ARBs and ARNIs. Although there was considerably greater compliance with GDMT, with approximately one third of pts fulfilling GMDT, opportunities still remain for improvement. Further investigation is needed to determine what influence greater compliance with GDMT may have on improved clinical outcomes such as reductions in VT/VF event rates and all-cause mortality.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehad655.344</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>European heart journal, 2023-11, Vol.44 (Supplement_2)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids></links><search><creatorcontrib>Mont, L</creatorcontrib><creatorcontrib>Daubert, J</creatorcontrib><creatorcontrib>Kutyifa, V</creatorcontrib><creatorcontrib>Zareba, W</creatorcontrib><creatorcontrib>Ando, K</creatorcontrib><creatorcontrib>Wold, N</creatorcontrib><creatorcontrib>Yong, P</creatorcontrib><creatorcontrib>Schuger, C</creatorcontrib><title>Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study</title><title>European heart journal</title><description>Abstract Introduction Patients (pts) implanted with an ICD for a primary prevention (PP) typically receive concomitant medications (meds) to treat LV dysfunction. However, It is not well established whether compliance with guideline-directed medical therapy (GDMT) has improved over time in this population. Methods Data were drawn from the MADIT-RIT (2009-2012) and APPRAISE ATP (2016-present) studies. Both studies were global in scope and enrolled pts who were implanted with an ICD for PP indications. Meds prescribed at baseline were compared between the two studies. Meds of interest included: evidence-based beta blockers [(BB-EV) defined as carvedilol, metoprolol, and bisoprolol], ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists (MRA). SGLT2i were introduced into GDMT after the study APPRAISE ATP started and were not included. Meds were analyzed both individually and in combination as GDMT, defined as joint use of BB-EV, ACE/ARB/ARNI, and MRA. Differences were compared with a t-test for continuous variables, a Chi-square test for categorical data and a Cochran-Armitage trend test for ordinal categorical data. Results Demographics for the two studies were compared for pts who received ICDs in MADIT-RIT (n=742) and APPRAISE ATP (n=2627 enrolled with n=2596 randomized) and are shown in the table below. When compared to MADIT-RIT, APPRAISE ATP pts were significantly older with a greater prevalence of diabetes. Comparison of baseline meds are shown in both the table and in the figure. Although BB-EV and ACE/ARB use was slightly but significantly lower in APPRAISE ATP, these declines were offset by a significant increase in MRA use in APPRAISE ATP. A marked shift was seen over time with significant decline in use of ACE-I that was matched by a significant increase in use of ARBs, either alone or in combination with ARNIs. When considering meds used in combination for GDMT, pts in APPRAISE ATP were significantly more likely to meet GDMT recommendations than pts who were enrolled in MADIT-RIT (36.7% vs 27.2%, respectively, p&lt;0.001). Conclusions In the APPRAISE ATP study, compliance with GDMT in PP ICD pts has significantly improved when compared to the MADIT-RIT study conducted 10 years previously. These changes have been characterized by greater use of MRAs as well as a shift away from ACE inhibitors towards use of ARBs and ARNIs. Although there was considerably greater compliance with GDMT, with approximately one third of pts fulfilling GMDT, opportunities still remain for improvement. Further investigation is needed to determine what influence greater compliance with GDMT may have on improved clinical outcomes such as reductions in VT/VF event rates and all-cause mortality.</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkNFKwzAUhoMoOKePIJwX6JakTeiupMzpCgOHTvCupGliM2xTkmywV_Cpzdzw2pvz8x_Of87hQ-ie4AnBs3Sqdq5VwoXtVLWi4YxN0iy7QCPCKE1mPGOXaITJjCWc5x_X6Mb7LcY454SP0PdSeAitgp1XYDVI20vbmSD6AFK4xggJnWqMFMHY3oPpBmf3qoFYHATTKTA9DM50wh2iqr3qj5NQzh9hiKFo_QOUvTefbfCgne1-7xXr9WtRvi2g2KzBh11zuEVXWnx5dXfWMXp_Wmzmy2T18lzOi1UiKc6yhFCCCVUZ1lzWtNZ1TlXNuEw5T2mdRs-EzrHMJWa14pQLqRtJGhwbQqUkHSN22iud9d4pXZ3frwiujkCrP6DVGWgVgcYcPuXsbvhn5AenVoC6</recordid><startdate>20231109</startdate><enddate>20231109</enddate><creator>Mont, L</creator><creator>Daubert, J</creator><creator>Kutyifa, V</creator><creator>Zareba, W</creator><creator>Ando, K</creator><creator>Wold, N</creator><creator>Yong, P</creator><creator>Schuger, C</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231109</creationdate><title>Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study</title><author>Mont, L ; Daubert, J ; Kutyifa, V ; Zareba, W ; Ando, K ; Wold, N ; Yong, P ; Schuger, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2044-121012e40f6cb2bfb82eb56c36632b3fb85af80c8c05be626acfdc1d08c0ae313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mont, L</creatorcontrib><creatorcontrib>Daubert, J</creatorcontrib><creatorcontrib>Kutyifa, V</creatorcontrib><creatorcontrib>Zareba, W</creatorcontrib><creatorcontrib>Ando, K</creatorcontrib><creatorcontrib>Wold, N</creatorcontrib><creatorcontrib>Yong, P</creatorcontrib><creatorcontrib>Schuger, C</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mont, L</au><au>Daubert, J</au><au>Kutyifa, V</au><au>Zareba, W</au><au>Ando, K</au><au>Wold, N</au><au>Yong, P</au><au>Schuger, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study</atitle><jtitle>European heart journal</jtitle><date>2023-11-09</date><risdate>2023</risdate><volume>44</volume><issue>Supplement_2</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Introduction Patients (pts) implanted with an ICD for a primary prevention (PP) typically receive concomitant medications (meds) to treat LV dysfunction. However, It is not well established whether compliance with guideline-directed medical therapy (GDMT) has improved over time in this population. Methods Data were drawn from the MADIT-RIT (2009-2012) and APPRAISE ATP (2016-present) studies. Both studies were global in scope and enrolled pts who were implanted with an ICD for PP indications. Meds prescribed at baseline were compared between the two studies. Meds of interest included: evidence-based beta blockers [(BB-EV) defined as carvedilol, metoprolol, and bisoprolol], ACE inhibitors, ARBs, ARNIs, and mineralocorticoid receptor antagonists (MRA). SGLT2i were introduced into GDMT after the study APPRAISE ATP started and were not included. Meds were analyzed both individually and in combination as GDMT, defined as joint use of BB-EV, ACE/ARB/ARNI, and MRA. Differences were compared with a t-test for continuous variables, a Chi-square test for categorical data and a Cochran-Armitage trend test for ordinal categorical data. Results Demographics for the two studies were compared for pts who received ICDs in MADIT-RIT (n=742) and APPRAISE ATP (n=2627 enrolled with n=2596 randomized) and are shown in the table below. When compared to MADIT-RIT, APPRAISE ATP pts were significantly older with a greater prevalence of diabetes. Comparison of baseline meds are shown in both the table and in the figure. Although BB-EV and ACE/ARB use was slightly but significantly lower in APPRAISE ATP, these declines were offset by a significant increase in MRA use in APPRAISE ATP. A marked shift was seen over time with significant decline in use of ACE-I that was matched by a significant increase in use of ARBs, either alone or in combination with ARNIs. When considering meds used in combination for GDMT, pts in APPRAISE ATP were significantly more likely to meet GDMT recommendations than pts who were enrolled in MADIT-RIT (36.7% vs 27.2%, respectively, p&lt;0.001). Conclusions In the APPRAISE ATP study, compliance with GDMT in PP ICD pts has significantly improved when compared to the MADIT-RIT study conducted 10 years previously. These changes have been characterized by greater use of MRAs as well as a shift away from ACE inhibitors towards use of ARBs and ARNIs. Although there was considerably greater compliance with GDMT, with approximately one third of pts fulfilling GMDT, opportunities still remain for improvement. Further investigation is needed to determine what influence greater compliance with GDMT may have on improved clinical outcomes such as reductions in VT/VF event rates and all-cause mortality.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehad655.344</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2023-11, Vol.44 (Supplement_2)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehad655_344
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
title Has the use of concomitant cardiac medications improved over time in primary prevention ICD patients? Insights from the APPRAISE ATP study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A49%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Has%20the%20use%20of%20concomitant%20cardiac%20medications%20improved%20over%20time%20in%20primary%20prevention%20ICD%20patients?%20Insights%20from%20the%20APPRAISE%20ATP%20study&rft.jtitle=European%20heart%20journal&rft.au=Mont,%20L&rft.date=2023-11-09&rft.volume=44&rft.issue=Supplement_2&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehad655.344&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehad655.344%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehad655.344&rfr_iscdi=true